Natrunix ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 2 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05363891 (ClinicalTrials.gov) | June 15, 2022 | 2/5/2022 | Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis | Phase II, Double-blind, Placebo-Controlled, Randomized Trial Examining Natrunix in Combination With Methotrexate (+Folate) for the Treatment of Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: Natrunix;Drug: Placebo | XBiotech, Inc. | NULL | Not yet recruiting | 18 Years | N/A | All | 150 | Phase 2 | NULL |
| 2 | NCT05363917 (ClinicalTrials.gov) | June 15, 2022 | 2/5/2022 | Natrunix Versus Methotrexate in Rheumatoid Arthritis | Phase II Double-Blinded, Placebo-Controlled Randomized Study Examining the Safety and Efficacy of Natrunix Versus Methotrexate (+Folate) for the Treatment of Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: Natrunix with MTX placebo (+folate);Drug: Natrunix placebo with MTX (+folate) | XBiotech, Inc. | NULL | Not yet recruiting | 18 Years | N/A | All | 150 | Phase 2 | NULL |